Xanthatin induces cell cycle arrest at G2/M checkpoint and apoptosis via disrupting NF-κB pathway in A549 non-small-cell lung cancer cells

Molecules

Volumn 17, Issue 4, 2012, Pages 3736-3750

  Zhang, Lei ^a,b   Ruan, Junshan ^a   Yan, Linggeng ^a   Li, Weidong ^a   Wu, Yu ^a   Tao, Li ^a   Zhang, Feng ^a   Zheng, Shizhong ^a   Wang, Aiyun ^a   Lu, Yin ^a  

^a NANJING UNIVERSITY OF CHINESE MEDICINE   (China)

^b ANHUI PROVINCIAL HOSPITAL   (China)

Author keywords

Apoptosis; Cell cycle; Cytotoxicity; Non small cell lung cancer; Xanthatin

Indexed keywords

ANTINEOPLASTIC AGENT; FURAN DERIVATIVE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN P53; XANTHATIN;

APOPTOSIS; ARTICLE; CELL CYCLE CHECKPOINT; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; LUNG NON SMALL CELL CANCER; LUNG TUMOR; M PHASE CELL CYCLE CHECKPOINT; METABOLISM; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; FURANS; G2 PHASE CELL CYCLE CHECKPOINTS; HUMANS; LUNG NEOPLASMS; M PHASE CELL CYCLE CHECKPOINTS; NF-KAPPA B; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84860252660     PISSN: None     EISSN: 14203049     Source Type: Journal    
DOI: 10.3390/molecules17043736     Document Type: Article

References (30)

1. Demain, A.L.; Vaishnav, P. Natural products for cancer chemotherapy. Microb. Biotechnol. 2011, 4, 687-699.
2. Vasas, A.; Hohmann, J. Xanthane sesquiterpenoids: Structure, synthesis and biological activity. Nat. Prod. Rep. 2011, 28, 824-842.
3. Zhang, S.; Won, Y.K.; Ong, C.N.; Shen, H.M. Anti-cancer potential of sesquiterpene lactones: Bioactivity and molecular mechanisms. Curr. Med. Chem. Anticancer Agents 2005, 5, 239-249.
4. Ghantous, A.; Gali-Muhtasib, H.; Vuorela, H.; Saliba, N.A.; Darwiche, N. What made sesquiterpene lactones reach cancer clinical trials? Drug Discov. Today 2010, 15, 668-678.
5. Ramirez-Erosa, I.; Huang, Y.; Hickie, R.A.; Sutherland, R.G.; Barl, B. Xanthatin and xanthinosin from the burs of Xanthium strumarium L. as potential anticancer agents. Can. J. Physiol. Pharmacol. 2007, 85, 1160-1172.
6. Kovacs, A.; Vasas, A.; Forgo, P.; Rethy, B.; Zupko, I.; Hohmann, J. Xanthanolides with antitumour activity from Xanthium italicum. Z. Naturforsch. C 2009, 64, 343-349.
7. Maddika, S.; Ande, S.R.; Panigrahi, S.; Paranjothy, T.; Weglarczyk, K.; Zuse, A.; Eshraghi, M.; Manda, K.D.; Wiechec, E.; Los, M. Cell survival, cell death and cell cycle pathways are interconnected: Implications for cancer therapy. Drug Resist. Updat. 2007, 10, 13-29.
8. Wu, Y.; Zhou, B.P. Inflammation: A driving force speeds cancer metastasis. Cell Cycle 2009, 8, 3267-3273.
9. Yoon, J.H.; Lim, H.J.; Lee, H.J.; Kim, H.D.; Jeon, R.; Ryu, J.H. Inhibition of lipopolysaccharide-induced inducible nitric oxide synthase and cyclooxygenase-2 expression by xanthanolides isolated from Xanthium strumarium. Bioorg. Med. Chem. Lett. 2008, 18, 2179-2182.
10. Polager, S.; Ginsberg, D. p53 and E2f: Partners in life and death. Nat. Rev. Cancer 2009, 9, 738-748.
11. Hu, W.; Kavanagh, J.J. Anticancer therapy targeting the apoptotic pathway. Lancet Oncol. 2003, 4, 721-729.
12. Coultas, L.; Strasser, A. The role of the Bcl-2 protein family in cancer. Semin. Cancer Biol. 2003, 13, 115-123.
13. Lavrik, I.N.; Golks, A.; Krammer, P.H. Caspases: Pharmacological manipulation of cell death. J. Clin. Invest. 2005, 115, 2665-2672.
14. Penissi, A.B.; Vera, M.E.; Mariani, M.L.; Rudolph, M.I.; Cenal, J.P.; de Rosas, J.C.; Fogal, T.H.; Tonn, C.E.; Favier, L.S.; Giordano, O.S.; et al. Novel anti-ulcer alpha, beta-unsaturated lactones inhibit compound 48/80-induced mast cell degranulation. Eur. J. Pharmacol. 2009, 612, 122-130.
15. Roussakis, C.; Chinou, I.; Vayas, C.; Harvala, C.; Verbist, J.F. Cytotoxic activity of xanthatin and the crude extracts of Xanthium strumarium. Planta Med. 1994, 60, 473-474.
16. Takeda, S.; Matsuo, K.; Yaji, K.; Okajima-Miyazaki, S.; Harada, M.; Miyoshi, H.; Okamoto, Y.; Amamoto, T.; Shindo, M.; Omiecinski, C.J.; et al. (-)-Xanthatin selectively induces GADD45gamma and stimulates caspase-independent cell death in human breast cancer MDA-MB-231 cells. Chem. Res. Toxicol. 2011, 24, 855-865.
17. Schwartz, G.K.; Shah, M.A. Targeting the cell cycle: A new approach to cancer therapy. J. Clin. Oncol. 2005, 23, 9408-9421.
18. Poonepalli, A.; Banerjee, B.; Ramnarayanan, K.; Palanisamy, N.; Putti, T.C.; Hande, M.P. Telomere-mediated genomic instability and the clinico-pathological parameters in breast cancer. Genes Chromosomes Cancer 2008, 47, 1098-1109.
19. Siegel, R.M. Caspases at the crossroads of immune-cell life and death. Nat. Rev. Immunol. 2006, 6, 308-317.
20. Rowinsky, E.K. Targeted induction of apoptosis in cancer management: The emerging role of tumor necrosis factor-related apoptosis-inducing ligand receptor activating agents. J. Clin. Oncol. 2005, 23, 9394-9407.
21. Kawabe, T. G2 checkpoint abrogators as anticancer drugs. Mol. Cancer Ther. 2004, 3, 513-519.
22. Abraham, R.T. Cell cycle checkpoint signaling through the ATM and ATR kinases. Genes Dev. 2001, 15, 2177-2196.
23. Bartek, J.; Lukas, J. Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell 2003, 3, 421-429.
24. Bucher, N.; Britten, C.D. G2 checkpoint abrogation and checkpoint kinase-1 targeting in the treatment of cancer. Br. J. Cancer 2008, 98, 523-528.
25. Udayakumar, T.; Shareef, M.M.; Diaz, D.A.; Ahmed, M.M.; Pollack, A. The E2F1/Rb and p53/MDM2 pathways in DNA repair and apoptosis: Understanding the crosstalk to develop novel strategies for prostate cancer radiotherapy. Semin. Radiat. Oncol. 2010, 20, 258-266.
26. Leu, J.I.; Dumont, P.; Hafey, M.; Murphy, M.E.; George, D.L. Mitochondrial p53 activates Bak and causes disruption of a Bak-Mcl1 complex. Nat. Cell Biol. 2004, 6, 443-450.
27. Sarkar, F.H.; Li, Y. NF-kappaB: A potential target for cancer chemoprevention and therapy. Front. Biosci. 2008, 13, 2950-2959.
28. Hehner, S.P.; Heinrich, M.; Bork, P.M.; Vogt, M.; Ratter, F.; Lehmann, V.; Schulze-Osthoff, K.; Droge, W.; Schmitz, M.L. Sesquiterpene lactones specifically inhibit activation of NF-kappa B by preventing the degradation of I kappa B-alpha and I kappa B-beta. J. Biol. Chem. 1998, 273, 1288-1297.
29. Zhang, W.; Han, W.; Li, Y.; Zhang, S.; Zhao, D. Chemical constituents from Xanthium mongolicum. Zhongguo Zhong Yao Za Zhi 2009, 34, 1687-1689.
30. Coward, P.; Wada, H.G.; Falk, M.S.; Chan, S.D.; Meng, F.; Akil, H.; Conklin, B.R. Controlling signaling with a specifically designed Gi-coupled receptor. Proc. Natl. Acad. Sci. USA 1998, 95, 352-357.